朗壽智醫科技股份有限公司
Update:2026/11/12
Industries
Main Industry
Health Care
Main Product/Service
[CardioRenix]: A smart medical platform that integrates multi-biomarker real-time detection, clinical AI, and longitudinal health risk analysis (Longitudinal Risk Intelligence). Through its self-developed Matrix929™ and EvoRisk™ AI, the platform integrates biomarkers, clinical tests, physiological data, and medical standards (FHIR / LOINC) to provide personalized risk assessment, disease prediction, and clinical decision support. It assists medical teams in the early identification of high-risk populations for cardiovascular, kidney, and metabolic (CKM) diseases, thereby improving clinical efficiency, reducing readmission rates and healthcare costs, and driving the realization of preventive medicine and value-based healthcare.
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60469138
Status
Active
Number of Employees
0
Total Paid-in
Capital
500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
朗壽智醫科技股份有限公司 combines AI with multi-biomarker testing and long-term health risk analysis to assist medical teams in detecting high-risk patients earlier, providing precise clinical decisions, reducing rates of severe illness and rehospitalization, improving healthcare efficiency, and implementing preventive medicine and value-based healthcare.
The content above was translated by Ai